Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study-Reference-Cited by-同舟云学术

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

Published:2018-04 Issue:4 Volume:19 Page:486-496
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Burris Howard A,Flinn Ian W,Patel Manish R,Fenske Timothy S,Deng Changchun,Brander Danielle M,Gutierrez Martin,Essell James H,Kuhn John G,Miskin Hari P,Sportelli Peter,Weiss Michael S,Vakkalanka Swaroop,Savona Michael R,O'Connor Owen A

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. The B-cell receptor signaling pathway as a therapeutic target in CLL;Woyach;Blood,2012

2. Signaling by the phosphoinositide 3-kinase family in immune cells;Okkenhaug;Ann Rev Immunol,2013

3. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies;Puri;Front Immunol,2012

4. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia;Furman;N Engl J Med,2014

5. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma;Gopal;N Engl J Med,2014

Cited by 182 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A highly selective PI3Kδ inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon;Neoplasia;2024-11

2. PI3K Inhibitors in Hematology: When One Door Closes…;Clinical Cancer Research;2024-07-05

3. Cryo-EM structures reveal two allosteric inhibition modes of PI3KαH1047R involving a re-shaping of the activation loop;Structure;2024-07

4. Fluorine in the pharmaceutical industry: Synthetic approaches and application of clinically approved fluorine-enriched anti-infectious medications;European Journal of Medicinal Chemistry;2024-05

5. Learnings from phosphatidylinositol 3‐kinase inhibitors in lymphoma—Moving to a model where less can be more;British Journal of Haematology;2024-04-06